サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1398316

脂質ナノ粒子製造の世界市場：サービス・技術 (脂質ナノ粒子の種類別・供給される分子の種類別・企業規模別・対象治療領域別・エンドユーザー別・主要地域別)：業界動向と世界の予測 (2023年～2035年)

Lipid Nanoparticle Manufacturing Market: Services & Technologies-Distribution by Type of Lipid Nanoparticle & Molecule Delivered, Company Size, Target Therapeutic Area, End-user, Key Geographical Regions: Industry Trends & Global Forecasts, 2023-2035
出版日: | 発行: Roots Analysis | ページ情報: 英文 290 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
脂質ナノ粒子製造の世界市場：サービス・技術 (脂質ナノ粒子の種類別・供給される分子の種類別・企業規模別・対象治療領域別・エンドユーザー別・主要地域別)：業界動向と世界の予測 (2023年～2035年)
出版日: 2023年10月29日
発行: Roots Analysis
ページ情報: 英文 290 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

世界の脂質ナノ粒子製造の市場規模は、2023年に6億6,000万米ドルに達し、予測期間中 (2023年～2035年) に11.8%のCAGRで成長しています。

近年、製薬業界は大幅な拡大を経験しており、前臨床試験や臨床試験で承認中または探索中の医薬品の数が増加していることからも明らかです。しかし、医薬品開発における根強いハードルは、多くの化合物の水溶性とバイオアベイラビリティの低さにあります。開発中の医薬品のおよそ90%、既存の薬理学的製剤の40%近くが、溶解性や浸透性に関する課題に直面しています。これらの問題は、吸収される前に体外に排出され、有効性に影響を与えることが多いです。そのため、製薬企業はこれらの障害を克服する解決策を積極的に模索しています。治療薬の溶解性とバイオアベイラビリティを高める様々な戦略の中で、脂質ナノ粒子 (LNP) と同様の脂質ベースの添加剤は、医薬品開発者から大きな注目を集めています。LNPは、多様な分子をカプセル化し、薬物放出を制御できることから、ナノメディシン・デリバリーにおける汎用性の高いプラットフォームとして認識されています。この分野の研究が盛んになるにつれ、ドラッグデリバリーにおけるLNPの利用に関する知的資本も拡大しています。

しかし、脂質ナノ粒子の製造は複雑でコスト集約的なプロセスであり、多様な専門知識が要求されます。そのため、製薬企業は、技術的・業務的課題に取り組むために必要な技術とノウハウを備えた専門の受託製造機関 (CMO) に依存するようになってきています。このようなサービスプロバイダーに外注化することで、スポンサーは革新的なLNP技術を活用し、業務の柔軟性を得ることができます。LNP固有の利点 (小型、多機能特性、カスタマイズ可能な表面) を考慮すると、LNPベースの治療薬市場は当面大きく成長する見込みです。この成長は、結果として予測期間中の脂質ナノ粒子製造市場の拡大を促進するでしょう。

当レポートでは、世界の資質ナノ粒子製造 (サービス・技術) の市場について分析し、資質ナノ粒子の概略や市場の最新情勢、主な市場促進・抑制要因、全体的な市場規模の動向見通し、セグメント別・地域別の詳細動向、昨今の主な資本取引・事業提携の動き、主要企業のプロファイルなどを調査しております。

市場の主要企業

  • Acuitas Therapeutics
  • Ascendia Pharmaceuticals
  • Avanti Polar Lipids
  • BIOVECTRA
  • CordenPharma
  • Creative Biolabs
  • Curapath
  • Curia
  • Emergent Biosolutions
  • EUROAPI
  • Evonik
  • Formumax Scientific
  • Fresinius Kabi
  • Fujifilm
  • Integrated Nanotherapeutics
  • leon-nanodrugs
  • Matinas BioPharma
  • Merck
  • Pantherna Therapeutics
  • Precision NanoSystems
  • TLC Biosciences

目次

第1章 序文

第2章 分析手法

第3章 経済およびその他のプロジェクト特有の考慮事項

第4章 エグゼクティブサマリー

第5章 イントロダクション

  • 分析概要
  • 脂質の概要
  • 脂質ナノ粒子の概要
  • 脂質ナノ粒子の製造に伴う課題
  • 脂質ナノ粒子製造の外注化の必要性
  • 結論

第6章 脂質ナノ粒子：サービスプロバイダーの情勢

  • 分析概要
  • 脂質ナノ粒子製造：サービスプロバイダーの一覧

第7章 脂質ナノ粒子：技術情勢

  • 分析概要
  • 脂質ナノ粒子：技術情勢
  • 脂質ナノ粒子技術：技術開発者の一覧

第8章 その他の種類の脂質：サービスプロバイダーの情勢

  • 分析概要
  • その他の種類の脂質：サービスプロバイダーの一覧

第9章 企業の競争力分析

  • 分析概要
  • 前提条件と主要なパラメーター
  • 分析手法
  • 脂質ナノ粒子製造サービスプロバイダー：企業の競争力分析

第10章 技術の競争力分析

  • 分析概要
  • 前提条件と主要なパラメーター
  • 分析手法
  • 脂質ナノ粒子技術：競争力分析

第11章 企業プロファイル：脂質ナノ粒子のサービスプロバイダー

  • 分析概要
  • Curia
  • Emergent BioSolutions
  • EUROAPI
  • Evonik
  • Ardena
  • BIOVECTRA
  • Company Overview
  • Precision NanoSystems

第12章 企業プロファイル：脂質ナノ粒子技術の開発者

  • 分析概要
  • Ascendia Pharmaceuticals
  • leon-nanodrugs
  • Pantherna Therapeutics
  • TLC Biosciences
  • Acuitas Therapeutics
  • Integrated Nanotherapeutics
  • Matinas BioPharma

第13章 企業プロファイル：その他の種類の脂質のサービスプロバイダー

  • 分析概要
  • Avanti Polar Lipids
  • Corden Pharma
  • Fujifilm
  • Merck
  • FormuMax Scientific
  • Creative Biolabs
  • Fresenius Kabi

第14章 事業提携・協力

  • 分析概要
  • 事業提携モデル
  • 脂質ナノ粒子のサービス・技術：事業提携・協力の一覧

第15章 可能性の高いパートナーの分析

  • 分析概要
  • 分析手法
  • mRNA医薬品開発者：北米における潜在的な戦略的パートナー
  • mRNA医薬品開発者：欧州・アジア太平洋における潜在的な戦略的パートナー

第16章 購入か、購入か：意思決定の枠組み

  • 分析概要
  • 前提条件と主要なパラメーター
  • 脂質ナノ粒子サービスプロバイダー：「製造か、購入か」の意思意思決定の枠組み
  • 結論

第17章 生産能力の分析

  • 分析概要
  • 重要な前提と分析手法
  • 世界中に導入されている脂質ナノ粒子の受託製造能力

第18章 市場への影響分析：促進要因、抑制要因、機会、課題

  • 分析概要
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の課題
  • 結論

第19章 世界の脂質ナノ粒子製造市場

  • 分析概要
  • 前提と分析手法
  • 世界の脂質ナノ粒子製造市場：過去の動向 (2018年～2022年) と予測 (2023年～2035年)
  • 主要な市場セグメンテーション

第20章 脂質ナノ粒子製造市場：脂質ナノ粒子の種類別

  • 分析概要
  • 重要な前提と分析手法
  • 脂質ナノ粒子製造市場：脂質ナノ粒子の種類別 (2018年、2023年、2035年)
  • データの計測と検証

第21章 脂質ナノ粒子製造市場、供給される分子の種類別

  • 分析概要
  • 重要な前提と分析手法
  • 脂質ナノ粒子製造市場：供給される分子の種類別 (2018年、2023年、2035年)
  • データの計測と検証

第22章 脂質ナノ粒子製造市場：企業規模別

  • 分析概要
  • 重要な前提と分析手法
  • 脂質ナノ粒子製造市場：企業規模別 (2018年、2023年、2035年)
  • データの計測と検証

第23章 脂質ナノ粒子製造市場：対象治療領域別

  • 分析概要
  • 重要な前提と分析手法
  • 脂質ナノ粒子製造市場：対象治療領域別 (2018年、2023年、2035年)
  • データの計測と検証

第24章 脂質ナノ粒子製造市場：エンドユーザーの種類別

  • 分析概要
  • 重要な前提と分析手法
  • 脂質ナノ粒子製造市場：エンドユーザーの種類別 (2018年、2023年、2035年)
  • データの計測と検証

第25章 脂質ナノ粒子製造市場：主要地域別

  • 分析概要
  • 重要な前提と分析手法
  • 脂質ナノ粒子製造市場：主要地域別 (2018年、2023年、2035年)
  • データの計測と検証

第26章 結論

第27章 経営陣の考察

  • 分析概要
  • LIPOSOMA
  • BIOVECTRA
  • OZ Biosciences

第28章 付録1：表形式のデータ

第29章 付録2：企業・組織の一覧

目次
Product Code: RA100461

The global lipid nanoparticle manufacturing market is valued at USD 0.66 billion in 2023 growing at a CAGR of 11.8% during the forecast period 2023-2035.

In recent years, the pharmaceutical industry has experienced significant expansion, evident in the increasing number of drugs undergoing approval or exploration in preclinical studies and clinical trials. However, a persistent hurdle in drug development lies in the poor water solubility and bioavailability of many compounds. Roughly 90% of drugs in development and nearly 40% of existing pharmacological products face challenges regarding solubility or permeability. These issues often lead to premature elimination from the body before they can be absorbed, impacting their effectiveness. Consequently, pharmaceutical firms are actively seeking solutions to overcome these obstacles. Among the various strategies to enhance the solubility and bioavailability of therapeutic agents, lipid nanoparticles (LNPs) and similar lipid-based additives have attracted substantial attention from drug developers. LNPs are recognized as a versatile platform in nanomedicine delivery due to their capacity to encapsulate diverse molecules and offer controlled drug release. As research in this field flourishes, the intellectual capital concerning the use of LNPs in drug delivery has also expanded.

Yet, manufacturing lipid nanoparticles is a complex and cost-intensive process that demands diverse expertise. Thus, pharmaceutical companies increasingly rely on specialized contract manufacturing organizations (CMOs) equipped with the necessary technology and know-how to tackle technical and operational challenges. Outsourcing to such service providers allows sponsors to tap into innovative LNP technologies and gain operational flexibility. Given the inherent advantages of LNPs-small size, multifunctional properties, and customizable surfaces-the market for LNP-based therapeutics is poised for significant growth in the foreseeable future. This growth will consequently drive expansion in the lipid nanoparticle manufacturing market during the projected period.

Key Market Segments:

Type of Lipid Nanoparticle

  • Solid Lipid Nanoparticles
  • Nanostructured Lipid Carriers

Type of Molecule Delivered

  • Nucleic Acids
  • Small Molecules
  • Peptides/ Proteins
  • Others

Company Size

  • Very Large and Large
  • Mid-sized
  • Small

Therapeutic Area

  • Infectious Diseases
  • Oncological Disorders
  • Blood Disorders
  • Rare Diseases
  • Other Disorders

Type of End User

  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes
  • Other End-users

Key Geographical Regions:

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Research Coverage:

  • The report studies the lipid nanoparticle manufacturing market based on type of lipid nanoparticle, type of molecule delivered, company size, target therapeutic area, type of end-user and key geographical regions
  • The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth
  • The report assesses the potential advantages and obstacles within the market for those involved and offers information on the competitive environment for top players in the market.
  • The report forecasts the revenue of market segments with respect to four major regions
  • Comprehensive methodology adopted for the study, encompassing assumptions, methodologies, and quality control measures for accuracy and reliability of findings.
  • Historical trends, currency fluctuations, foreign exchange impact, recession, and inflation measurements shaping the lipid nanoparticle manufacturing market.
  • High-level overview capturing current state and potential evolution of the lipid nanoparticle manufacturing market in the medium to long term.
  • Exploration of lipids, their types, advantages, applications in pharmaceuticals, challenges in formulation, and the rising need for outsourcing manufacturing operations.
  • Evaluation based on establishment year, company size, headquarters location, manufacturing facility location, operational scale, delivered molecule types, therapeutic areas, and additional services offered.
  • Evaluation based on formulation methods, molecule types, compatible dosage forms, administration routes, therapeutic areas, establishment year, company size, headquarters location, business models, and active players.
  • Examination based on establishment year, company size, headquarters location, manufacturing facilities, operational scale, lipid types, product types, additional services offered, and competitiveness analysis.
  • Comparative assessment of lipid nanoparticle contract manufacturing organizations based on company strength, service strength, and the number of manufacturing facilities.
  • Insightful analysis based on developer strength, technology aspects, and applicability in therapeutic areas.
  • Detailed profiles of key players in LNP manufacturing services and technology, featuring company overview, portfolios, recent developments, and future outlook.
  • Examination of partnerships between stakeholders since 2019, based on various parameters and regional distribution of involved companies.
  • Evaluation of mRNA vaccine and therapeutics developers for potential partnerships with lipid nanoparticle manufacturers, considering multiple criteria.
  • Detailed exploration of factors influencing the decision of companies to outsource LNP manufacturing or develop in-house capabilities.
  • Analysis of global installed capacity among LNP contract manufacturers based on company size, operational scale, and geographical distribution.
  • Identification and analysis of key drivers, potential restraints, emerging opportunities, and existing challenges impacting lipid nanoparticle manufacturing market growth.

Key Benefits of Buying this Report:

  • The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
  • Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
  • The report provides stakeholders with a pulse on the lipid nanoparticle manufacturing market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Key Market Companies:

  • Acuitas Therapeutics
  • Ascendia Pharmaceuticals
  • Avanti Polar Lipids
  • BIOVECTRA
  • CordenPharma
  • Creative Biolabs
  • Curapath
  • Curia
  • Emergent Biosolutions
  • EUROAPI
  • Evonik
  • Formumax Scientific
  • Fresinius Kabi
  • Fujifilm
  • Integrated Nanotherapeutics
  • leon-nanodrugs
  • Matinas BioPharma
  • Merck
  • Pantherna Therapeutics
  • Precision NanoSystems
  • TLC Biosciences

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Introduction
  • 1.2. Key Market Insights
  • 1.3. Scope of the Report
  • 1.4. Inclusions and Exclusions
  • 1.5. Key Questions Answered
  • 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
  • 2.3. Project Methodology
  • 2.4. Forecast Methodology
  • 2.5. Robust Quality Control
  • 2.6. Key Market Segmentations
  • 2.7. Key Considerations
    • 2.7.1. Demographics
    • 2.7.2. Economic Factors
    • 2.7.3. Government Regulations
    • 2.7.4. Supply Chain
    • 2.7.5. COVID Impact / Related Factors
    • 2.7.6. Market Access
    • 2.7.7. Healthcare Policies
    • 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

  • 3.1. Chapter Overview
  • 3.2. Market Dynamics
    • 3.2.1. Time Period
      • 3.2.1.1. Historical Trends
      • 3.2.1.2. Current and Forecasted Estimates
    • 3.2.2. Currency Coverage
      • 3.2.2.1. Overview of Major Currencies Affecting the Market
      • 3.2.2.2. Impact of Currency Fluctuations on the Industry
    • 3.2.3. Foreign Exchange Impact
      • 3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
      • 3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
    • 3.2.4. Recession
      • 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
      • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 3.2.5. Inflation
      • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

  • 5.1. Chapter Overview
  • 5.2. Overview of Lipids
  • 5.3 Introduction to Lipid Nanoparticles
    • 5.3.1. Types of Lipid Nanoparticles
      • 5.3.1.1. Solid Lipid Nanoparticles
      • 5.3.1.2. Nanostructured Lipid Carriers
    • 5.3.2. Advantages of Lipid Nanoparticles
    • 5.3.3. Applications of Lipid Nanoparticles in Pharmaceutical Industry
      • 5.3.3.1. Cancer Treatment
      • 5.3.3.2. Gene Therapy
      • 5.3.3.3. Vaccine Development
      • 5.3.3.4. Medical Imaging / Diagnostics
      • 5.3.3.5. Additional Applications
  • 5.4. Challenges Associated with Lipid Nanoparticle Manufacturing
  • 5.5. Need for Outsourcing Lipid Nanoparticle Manufacturing
  • 5.6. Concluding Remarks

6. LIPID NANOPARTICLES: SERVICE PROVIDERS LANDSCAPE

  • 6.1. Chapter Overview
  • 6.2. Lipid Nanoparticle Manufacturing: List of Service Providers
    • 6.2.1 Analysis by Year of Establishment
    • 6.2.2 Analysis by Company Size
    • 6.2.3 Analysis by Location of Headquarters
    • 6.2.4 Analysis by Company Size and Location of Headquarters
    • 6.2.5 Analysis by Location of Lipid Nanoparticle Manufacturing Facility
    • 6.2.6 Analysis by Scale of Operation
    • 6.2.7 Analysis by Type of Molecule Delivered
    • 6.2.8 Analysis by Therapeutic Area
    • 6.2.9 Analysis by Type of Additional Services Offered

7. LIPID NANOPARTICLES: TECHNOLOGY LANDSCAPE

  • 7.1. Chapter Overview
  • 7.2. Lipid Nanoparticle: Technology Landscape
    • 7.2.1. Analysis by Type of Formulation Method
    • 7.2.2. Analysis by Type of Molecule Delivered
    • 7.2.3. Analysis by Compatible Dosage Form
    • 7.2.4. Analysis by Routes of Administration
    • 7.2.5. Analysis by Therapeutic Area
  • 7.3. Lipid Nanoparticle Technologies: List of Technology Developers
    • 7.3.1. Analysis by Year of Establishment
    • 7.3.2. Analysis by Company Size
    • 7.3.3. Analysis by Location of Headquarters
    • 7.3.4. Analysis by Company Size and Location of Headquarters
    • 7.3.5. Analysis by Business Model
    • 7.3.6. Most Active Players: Analysis by Number of Technologies

8. OTHER TYPES OF LIPIDS: SERVICE PROVIDERS LANDSCAPE

  • 8.1. Chapter Overview
  • 8.2. Other Types of Lipids: List of Service Providers
    • 8.2.1 Analysis by Year of Establishment
    • 8.2.2 Analysis by Company Size
    • 8.2.3 Analysis by Location of Headquarters
    • 8.2.4 Analysis by Company Size and Location of Headquarters
    • 8.2.5. Analysis by Location of Manufacturing Facility
    • 8.2.6. Analysis by Scale of Operation
    • 8.2.7 Analysis by Type of Lipid Manufactured
    • 8.2.8. Analysis by Scale of Operation and Type of Lipid Manufactured
    • 8.2.9. Analysis by Type of Product
    • 8.2.10. Analysis by Type of Additional Services Offered
    • 8.2.11. Analysis by Type of Product and Type of Additional Services Offered

9. COMPANY COMPETITIVENESS ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Assumptions and Key Parameters
  • 9.3. Methodology
  • 9.4. Lipid Nanoparticle Manufacturing Service Providers: Company Competitiveness Analysis
    • 9.4.1. Company Competitiveness Analysis: Small Players
    • 9.4.2. Company Competitiveness Analysis : Mid-sized Players
    • 9.4.3. Company Competitiveness Analysis : Large and Very Large Players

10. TECHNOLOGY COMPETITIVENESS ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Assumptions and Key Parameters
  • 10.3. Methodology
  • 10.4. Lipid Nanoparticle Technologies: Competitiveness Analysis
    • 10.4.1. Technology Competitiveness Analysis: Players based in North America
    • 10.4.2. Technology Competitiveness Analysis: Players based in Europe and Asia-Pacific

11. COMPANY PROFILES: SERVICE PROVIDERS OF LIPID NANOPARTICLES

  • 11.1. Chapter Overview
  • 11.2. Curia
    • 11.2.1. Company Overview
    • 11.2.2. Service Portfolio
    • 11.2.3. Recent Developments and Future Outlook
  • 11.3. Emergent BioSolutions
    • 11.3.1. Company Overview
    • 11.3.2. Service Portfolio
    • 11.3.3. Recent Developments and Future Outlook
  • 11.4. EUROAPI
    • 11.4.1. Company Overview
    • 11.4.2. Service Portfolio
    • 11.4.3. Recent Developments and Future Outlook
  • 11.5. Evonik
    • 11.5.1. Company Overview
    • 11.5.2. Service Portfolio
    • 11.5.3. Recent Developments and Future Outlook
  • 11.6. Ardena
    • 11.6.1. Company Overview
    • 11.6.2. Service Portfolio
  • 11.7. BIOVECTRA
  • 117.1. Company Overview
    • 11.7.2. Service Portfolio
  • 11.8. Precision NanoSystems
    • 11.8.1. Company Overview
    • 11.8.2. Service Portfolio

12. COMPANY PROFILES: LIPID NANOPARTICLE TECHNOLOGY DEVELOPERS

  • 12.1. Chapter Overview
  • 12.2. Ascendia Pharmaceuticals
    • 12.2.1. Company Overview
    • 12.2.2. Lipid Nanoparticle Technology Portfolio
    • 12.2.3. Recent Developments and Future Outlook
  • 12.3. leon-nanodrugs
    • 12.3.1. Company Overview
    • 12.3.2. Lipid Nanoparticle Technology Portfolio
    • 12.3.3. Recent Developments and Future Outlook
  • 12.4. Pantherna Therapeutics
    • 12.4.1. Company Overview
    • 12.4.2. Lipid Nanoparticle Technology Portfolio
    • 12.4.3. Recent Developments and Future Outlook
  • 12.5. TLC Biosciences
    • 12.5.1. Company Overview
    • 12.5.2. Lipid Nanoparticle Technology Portfolio
    • 12.5.3. Recent Developments and Future Outlook
  • 12.6. Acuitas Therapeutics
    • 12.6.1. Company Overview
    • 12.6.2. Service Portfolio
  • 12.7. Integrated Nanotherapeutics
    • 12.7.1. Company Overview
    • 12.7.2. Service Portfolio
  • 12.8. Matinas BioPharma
    • 12.8.1. Company Overview
    • 12.8.2. Service Portfolio

13. COMPANY PROFILES: SERVICE PROVIDERS OF OTHER TYPES OF LIPIDS

  • 13.1. Chapter Overview
  • 13.2. Avanti Polar Lipids
    • 13.2.1. Company Overview
    • 13.2.2. Service Portfolio
    • 13.2.3. Recent Developments and Future Outlook
  • 13.3. Corden Pharma
    • 13.3.1. Company Overview
    • 13.3.2. Service Portfolio
    • 13.3.3. Recent Developments and Future Outlook
  • 13.4. Fujifilm
    • 13.4.1. Company Overview
    • 13.4.2. Service Portfolio
    • 13.4.3. Recent Developments and Future Outlook
  • 13.5. Merck
    • 13.5.1. Company Overview
    • 13.5.2. Service Portfolio
    • 13.5.3. Recent Developments and Future Outlook
  • 13.6. FormuMax Scientific
    • 13.6.1. Company Overview
    • 12.6.2. Service Portfolio
  • 13.7. Creative Biolabs
    • 13.7.1. Company Overview
    • 13.7.2. Service Portfolio
  • 13.8. Fresenius Kabi
    • 13.8.1. Company Overview
    • 13.8.2. Service Portfolio

14. PARTNERSHIPS AND COLLABORATIONS

  • 14.1. Chapter Overview
  • 14.2. Partnership Models
  • 14.3. Lipid Nanoparticles Services and Technologies: List of Partnerships and Collaborations
    • 14.3.1. Analysis by Year of Partnership
    • 14.3.2. Analysis by Type of Partnership
    • 14.3.3. Analysis by Year and Type of Partnership
    • 14.3.4. Analysis by Type of Molecule
    • 14.3.5. Analysis by Therapeutic Area
    • 14.3.6. Analysis by Type of Partner
    • 14.3.7. Most Active Players: Analysis by Number of Partnerships
    • 14.3.8. Analysis by Geography
      • 14.3.8.1. Intracontinental and Intercontinental Deals
      • 14.3.8.2. International and Local Deals

15. LIKELY PARTNER ANALYSIS

  • 15.1. Chapter Overview
  • 15.2. Methodology
  • 15.2. mRNA Drug Developers: Potential Strategic Partners in North America
  • 15.3. mRNA Drug Developers: Potential Strategic Partners in Europe and Asia-Pacific

16. MAKE VERSUS BUY DECISION FRAMEWORK

  • 16.1. Chapter Overview
  • 16.2. Assumptions and Key Parameters
  • 16.3. Lipid Nanoparticle Service Providers: Make versus Buy Decision Making Framework
    • 16.3.1. Scenario 1
    • 16.3.2. Scenario 2
    • 16.3.3. Scenario 3
    • 16.3.4. Scenario 4
  • 16.4. Concluding Remarks

17. CAPACITY ANALYSIS

  • 17.1. Chapter Overview
  • 17.2. Key Assumptions and Methodology
  • 17.3. Global Installed Lipid Nanoparticle Contract Manufacturing Capacity
    • 17.3.1. Analysis by Range of Installed Capacity
    • 17.3.2. Analysis by Company Size
    • 17.3.3. Analysis by Scale of Operation
    • 17.3.4. Analysis by Location of Manufacturing Facility
      • 17.3.4.1. Analysis of Installed Lipid Nanoparticle Contract Manufacturing Capacity in North America
      • 17.3.4.2. Analysis of Installed Lipid Nanoparticle Contract Manufacturing Capacity in Europe
      • 17.3.4.3. Analysis of Installed Lipid Nanoparticle Contract Manufacturing Capacity in Asia-Pacific
    • 17.3.5. Concluding Remarks

18. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

  • 18.1. Chapter Overview
  • 18.2. Market Drivers
  • 18.3. Market Restraints
  • 18.4. Market Opportunities
  • 18.5. Market Challenges
  • 18.6. Conclusion

19. GLOBAL LIPID NANOPARTICLE MANUFACTURING MARKET

  • 19.1. Chapter Overview
  • 19.2. Assumptions and Methodology
  • 19.3. Global Lipid Nanoparticle Manufacturing Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 19.3.1. Scenario Analysis
      • 19.3.1.1. Conservative Scenario
      • 19.3.1.2. Optimistic Scenario
  • 19.4. Key Market Segmentations

20. LIPID NANOPARTICLE MANUFACTURING MARKET, BY TYPE OF LIPID NANOPARTICLE

  • 20.1. Chapter Overview
  • 20.2. Key Assumptions and Methodology
  • 20.3. Lipid Nanoparticle Manufacturing Market: Distribution by Type of Lipid Nanoparticle, 2028, 2023 and 2035
    • 20.3.1. Solid Lipid Nanoparticles, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 20.3.2. Nanostructured Lipid Carriers, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 20.7. Data Triangulation and Validation

21. LIPID NANOPARTICLE MANUFACTURING MARKET, BY TYPE OF MOLECULE DELIVERED

  • 21.1. Chapter Overview
  • 21.2. Key Assumptions and Methodology
  • 21.3. Lipid Nanoparticle Manufacturing Market: Distribution by Type of Molecule Delivered, 2018, 2023 and 2035
    • 21.3.1. Nucleic Acids, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 21.3.2. Small Molecules, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 21.3.3. Peptides / Proteins, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 21.3.4. Other Molecules, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 21.4. Data Triangulation and Validation

22. LIPID NANOPARTICLE MANUFACTURING MARKET, BY COMPANY SIZE

  • 22.1. Chapter Overview
  • 22.2. Key Assumptions and Methodology
  • 22.3. Lipid Nanoparticle Manufacturing Market: Distribution by Company Size, 2018, 2023 and 2035
    • 22.3.1. Very Large and Large Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 22.3.2. Mid-sized Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 22.3.3. Small Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 22.4. Data Triangulation and Validation

23. LIPID NANOPARTICLE MANUFACTURING MARKET, BY TARGET THERAPEUTIC AREA

  • 23.1. Chapter Overview
  • 23.2. Key Assumptions and Methodology
  • 23.3. Lipid Nanoparticle Manufacturing Market: Distribution by Target Therapeutic Area, 2018, 2023 and 2035
    • 23.3.1. Infectious Diseases, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 23.3.2. Oncological Disorders, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 23.3.3. Blood Disorders, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 23.3.4. Rare Diseases, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 23.3.5. Other Disorders, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 23.4. Data Triangulation and Validation

24. LIPID NANOPARTICLE MANUFACTURING MARKET, BY TYPE OF END-USER

  • 24.1. Chapter Overview
  • 24.2. Key Assumptions and Methodology
  • 24.3. Lipid Nanoparticle Manufacturing Market: Distribution by Type of End-user, 2018, 2023 and 2035
    • 24.3.1. Pharmaceutical and Biotechnology Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 24.3.2. Academic and Research Institutes, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 24.3.3. Other End-Users: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 24.4. Data Triangulation and Validation

25. LIPID NANOPARTICLE MANUFACTURING MARKET, BY KEY GEOGRAPHICAL REGIONS

  • 25.1. Chapter Overview
  • 25.2. Key Assumptions and Methodology
  • 25.3. Lipid Nanoparticle Manufacturing Market: Distribution by Key Geographical Regions, 2018, 2023 and 2035
    • 25.3.1. North America, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 25.3.2. Europe, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 25.3.3. Asia-Pacific, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 25.3.4. Rest of the World, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 25.4. Data Triangulation and Validation

26. CONCLUSION

27. EXECUTIVE INSIGHTS

  • 27.1. Chapter Overview
  • 27.2. LIPOSOMA
    • 27.2.1. Company Snapshot
  • 27.3. BIOVECTRA
    • 27.3.1. Company Snapshot
  • 27.4. OZ Biosciences
    • 27.4.1. Company Snapshot

28. APPENDIX 1: TABULATED DATA

29. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION